Core Insights - On October 17, Xiaofang Pharmaceutical experienced a decline of 0.80% with a trading volume of 75.57 million yuan [1] - The company reported a financing buy-in amount of 13.82 million yuan and a net financing buy of 3.20 million yuan on the same day [1] - As of October 17, the total financing and securities lending balance for Xiaofang Pharmaceutical reached 112 million yuan, which is 6.13% of its market capitalization [1] Financing Summary - On October 17, Xiaofang Pharmaceutical had a financing buy-in of 13.82 million yuan, with a current financing balance of 112 million yuan, exceeding the 70th percentile of the past year [1] - The company had no securities lending activity on October 17, with a securities lending balance of 0 yuan, indicating a high level of inactivity in this area [1] Business Performance - As of September 19, the number of shareholders for Xiaofang Pharmaceutical was 13,500, a decrease of 8.81% from the previous period [2] - For the first half of 2025, the company achieved a revenue of 270 million yuan, representing a year-on-year growth of 3.06%, and a net profit of 121 million yuan, with a growth of 1.69% [2] - Since its A-share listing, Xiaofang Pharmaceutical has distributed a total of 353 million yuan in dividends [2] Shareholder Composition - As of June 30, 2025, the top ten circulating shareholders included new entrants such as CITIC Jiantou Rotation Mixed A and CITIC Jiantou Selection Mixed A, holding 439,400 shares and 298,100 shares respectively [2] - The fifth largest shareholder, Taixin Leading Strategy Mixed, maintained its holding of 256,800 shares, while Taixin Industry Selection Mixed A exited the top ten list [2]
小方制药10月17日获融资买入1381.92万元，融资余额1.12亿元